2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to ...

UD chemical engineer wins the AIChE Langer Prize for efforts to harness biology to manage plastic waste sustainably ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

The healthcare industry revolves around constant innovation in areas like biotechnology, pharmaceuticals, medical devices, and digital health. This innovation is leading to new treatments, diagnostic ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...